Wenzel Spine Debuts First FDA-Cleared Expandable SI Fusion Implant in Limited U.S. Launch

Austin, Texas–based Wenzel Spine has completed the first U.S. procedures using its panaSIa™ Expandable SI Fusion System, marking the start of a limited commercial launch ahead of full availability in Q4 2025. The device is the first expandable sacroiliac (SI) fusion implant cleared by the FDA, designed to address SI joint dysfunction with enhanced biomechanical stability and a streamlined surgical workflow.

The panaSIa implant is inserted through a posterior, minimally invasive approach, achieving fixation by expanding across the ilium and sacrum. This expansion provides immediate mechanical stability while preserving surrounding tissue. An integrated graft chamber enables bone grafting after expansion without removing instruments, promoting optimal fusion conditions and reducing procedural complexity.

Early cases have been performed at select surgical centers as part of the limited release. Dr. Aaron Calodney, an interventional pain medicine specialist, highlighted the implant’s ability to stabilize the joint and reduce pain by eliminating micro-motion and distracting arthritic surfaces.

The launch strengthens Wenzel Spine’s portfolio of stand-alone expandable fusion devices, reflecting nearly two decades of expertise in expandable implant design. CEO William Wilson described panaSIa as a precision-driven, minimally invasive solution that delivers control and speed to SI joint fusion procedures.

The system is available in two implant sizes for anatomical customization and features instrumentation tailored for true minimally invasive placement. Full U.S. release is planned for late 2025.